The efficacy and safety of vildagliptin in the GALIANT trial: chronic kidney disease and other applications

References

• McKennon SA, Campbell RK. The physiology of incretin hormones and the basis for DPP-4 inhibitors. Diabetes Educ.33, 55–66 (2007).
   PubMed Web of Science ®Google Scholar
• Gutzwiller JP, Drewe J, Goke B et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am. J. Physiol.276(5 Pt 2), R1541–R1544 (1999).
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of Type 2 diabetes. Diabetes Care30(6), 1335–1343 (2007).
   PubMed Web of Science ®Google Scholar
• Holst JJ, Toft-Nielsen MB, Orskov C, Nauck M, Willms B. On the effects of glucagon-like peptide-1 on blood glucose regulation in normal and diabetic subjects. Ann. NY Acad. Sci.805, 729–736 (1996).
   Web of Science ®Google Scholar
• Schirra J, Wank U, Arnold R, Goke B, Katschinski M. Effects of glucagon-like peptide 1 (7–36) amide on motility and sensation of the proximal stomach in humans. Gut50, 341–348 (2002).
   PubMedGoogle Scholar
• Nauck MA, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia29, 46–52 (1986).
   PubMed Web of Science ®Google Scholar
• Meier JJ, Nauck MA. Is the diminished incretin effect in Type 2 diabetes just an epi-phenomenon of impaired β-cell function? Diabetes59(5), 1117–1125 (2010).
   PubMed Web of Science ®Google Scholar
• Chia CW, Carlson OD, Kim W et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in Type 2 diabetes. Diabetes58(6), 1342–1349 (2009).
   PubMed Web of Science ®Google Scholar
• Balas B, Baig MR, Watson C et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients. J. Clin. Endocinol. Metab.92, 1249–1255 (2007).
   PubMed Web of Science ®Google Scholar
• Vella A, Bock G, Giesler PD et al. Effects of dipeptidyl peptidase 4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in Type 2 diabetes. Diabetes56, 14785–11480 (2007).
   Google Scholar
• He YL, Wang Y, Bullock JM et al. Pharmacodynamics of vildagliptin in patients with Type 2 diabetes during OGTT. J. Clin. Pharmacol.477, 633–641 (2007).
   Google Scholar
• Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over one year in drug-naïve patients with Type 2 diabetes. Diabet. Med.24, 955–961 (2007).
   PubMed Web of Science ®Google Scholar
• Blonde L, Dagogo-Jack S, Banerji MA et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial – a primary care, Type 2 diabetes study. Diabetes Obes. Metab.11, 978–986 (2009).
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Greene T et al. Chronic kidney disease epidemiology collaboration. Using standardized serum creatinine values in the modification of diet in renal disease (MDRD) study equation for estimating glomerular filtration rate. Ann. Intern. Med.145(4), 247–254 (2006).
   PubMed Web of Science ®Google Scholar
• Banerji MA, Burkayastha P, Francis BH. Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without renal impairment: a retrospective analysis of GALIANT study. Diabetes Res. Clin. Pract.90(2), 182–190 (2010).
   PubMed Web of Science ®Google Scholar
• Bolli G, Dotta F, Colin L, Minic B, Goodman M. Comparison of vildagliptin and pioglitazone in patients with Type 2 diabetes inadequately controlled with metformin. Diabetes Obes. Metab.11, 589–595 (2009).
   PubMed Web of Science ®Google Scholar
• Astor BC, Hallan SI, Miller ER 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am. J. Epidemiol.167(10), 1226–1234 (2008).
   PubMed Web of Science ®Google Scholar
• Rodbard H, Jellinger P, Davidson, J et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on Type 2 diabtes mellitus: an algorithm for glycemic control. Endocr. Pract.15(6), 540–559 (2009).
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med.358, 2560–2572 (2008).
   Google Scholar
• Pi-Sunyer FX, Schweizer A, Mills D et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with Type 2 diabetes. Diabetes Res. Clin. Pract.76, 132–138 (2007).
   PubMed Web of Science ®Google Scholar
• Garber AJ, Schweizer A, Baron MA et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with Type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes. Metab.9, 166–174 (2007).
   PubMed Web of Science ®Google Scholar
• Garber AJ, Foley JE, Banerji MA et al. Effects of vildagliptin on glucose control in patients with Type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes. Metab.10, 1047–1056 (2008).
   PubMed Web of Science ®Google Scholar
• Fonseca V, Schweizer A, Albrecht D et al. Addition of vildagliptin to insulin improves glycemic control in Type 2 diabetes. Diabetologia50, 1148–1155 (2007).
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med.359(15), 1577–1589 (2008).
   PubMed Web of Science ®Google Scholar
• Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of Type 1 diabetes mellitus. JAMA287, 2563–2569 (2002)
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Engl. J. Med.353, 2643–2653 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Foley JE, Rendell M et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care31(1), 30–35 (2008).
   PubMed Web of Science ®Google Scholar
• Ahren B, Schweizer S, Dejager S et al. Vildagliptin enhances islet responsiveness to both hyper-and hypoglycemia in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab.94, 1236–1243 (2009).
   PubMed Web of Science ®Google Scholar
• Foley J, Ligueros-Saylan M, He Y et al. Effect of vildagliptin on glucagon concentration during meals in patients with Type 1 diabetes. Hormone Metab. Res.40(10), 727–730 (2008).
   PubMed Web of Science ®Google Scholar
• Mu J, Woods J, Zhou YP et al. Chronic inhibition of dipeptidyly peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent with Type 2 diabetes. Diabetes55, 1695–1704 (2006).
   PubMed Web of Science ®Google Scholar
• Ahren B, Sorhede Winzell M, Weirup N et al. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with β-cell specific overexpression of human islet amyloid polypeptide. Regul. Pept.143, 97–103 (2007).
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab.3, 153–165 (2003).
   Google Scholar
• Farilla L, Bulotta A, Hirschberg B et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology144, 5149–5158 (2003).
   PubMed Web of Science ®Google Scholar
• D’Alessio D, Denney A, Hermiller L et al. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with Type 2 diabetes. J. Clin. Endocrinol. Metab.94, 81–88 (2009).
   PubMed Web of Science ®Google Scholar
• Matikainen N, Manttari S, Schweizer A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with Type 2 diabetes. Diabetologia49, 2049–2057 (2006).
   PubMed Web of Science ®Google Scholar
• Azuma K, Radikova Z, Mancino J et al. Measurements of islet cell function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with Type 2 diabetes. J. Clin. Endocinol. Metab.93, 459–464 (2008).
   PubMed Web of Science ®Google Scholar
• Boschmann M, Engeli S, Dobberstein K et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in Type 2 diabetic patients. J. Clin. Endocinol. Metab.94(3), 846–852 (2009).
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with Type 2 diabetes inadequately controlled with metformin alone. Diabetes Care29(12), 2638–2643 (2006).
   PubMed Web of Science ®Google Scholar
• Nikolaidis L, Mankad S, Sokos, G. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation109, 962–965 (2004).
   PubMed Web of Science ®Google Scholar
• Sokos GG, Bolukoglu H, German J et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am. J. Cardiol.100(5), 824–829 (2007).
   PubMed Web of Science ®Google Scholar
• Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cariovasc. Drug Ther.21, 253–256 (2007).
   PubMed Web of Science ®Google Scholar
• Noyan-Shraf MH, Momen MA, Ban K et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes58, 975–983 (2009).
   Google Scholar
• Ye Y, Keyes K, Zhang C, Perez-Polo J, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent whereas the protective effect of pioglitazone is partially dependent on PKA. Am. J. Physiol. Heart Circ. Physiol.298, H1454–H1465 (2010).
   PubMed Web of Science ®Google Scholar
• Lankas GR, Leiting B, Roy RS et al. Dipeptidyl peptidase IV inhibition for the treatment of Type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes54, 2988–2994 (2005).
   PubMed Web of Science ®Google Scholar
• Burkey BF, Hoffman PK, Hassiepen U et al. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes. Metab.10, 1057–1061 (2008).
   PubMed Web of Science ®Google Scholar
• Burkey BF, Hoffman PK, Hassiepen U et al. Adverse effects of dipeptidyl peptidases 8 and 9 inhibitions in rodents revisited. Diabetes Obes. Metab.10, 1057–1061 (2008).
   PubMed Web of Science ®Google Scholar
• Kirby M, Yu DM, O’Connor S et al. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin. Sci.118, 31–41 (2010).
   Web of Science ®Google Scholar
• Kim D, Wang L, Beconi M et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidylpeptidase IV inhibitor for the treatment of Type 2 diabetes. J. Med. Chem.48, 141–151 (2005).
   PubMed Web of Science ®Google Scholar
• Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in Type 2 diabetes: systematic review and metanalysis. JAMA298, 194–206 (2007).
   PubMed Web of Science ®Google Scholar